FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993422879> ?p ?o ?g. }

• W1993422879 endingPage "293" @default.
• W1993422879 startingPage "278" @default.
• W1993422879 abstract "CNS Drug ReviewsVolume 3, Issue 3 p. 278-293 Free Access Biochemical and Behavioral Pharmacology of RS-102221, a Subtype Selective 5-HT2c Receptor Antagonist D. W. Bonhaus, Corresponding Author D. W. Bonhaus Roche Bioscience, Palo Alto, CA 94304, USA.Address correspondence and reprint requests to Dr. D. W. Bonhaus, Department of Molecular Pharmacology, Roche Bioscience, Neurobiology Unit, 3401 Hillview Avenue, Building R2-101, Palo Alto CA 94304, USA. Fax: (650) 852-3111.Search for more papers by this authorK. K. Weinhardt, K. K. Weinhardt Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorM. Taylor, M. Taylor Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorA. DeSouza, A. DeSouza Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorP. M. McNeeley, P. M. McNeeley Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorK. Szczepanski, K. Szczepanski Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorD. J. Fontana, D. J. Fontana Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorJ. Trinh, J. Trinh Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorC. L. Rocha, C. L. Rocha Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorM. W. Dawson, M. W. Dawson Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorZ. Cao, Z. Cao Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorL. Wong, L. Wong Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorR. M. Eglen, R. M. Eglen Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this author D. W. Bonhaus, Corresponding Author D. W. Bonhaus Roche Bioscience, Palo Alto, CA 94304, USA.Address correspondence and reprint requests to Dr. D. W. Bonhaus, Department of Molecular Pharmacology, Roche Bioscience, Neurobiology Unit, 3401 Hillview Avenue, Building R2-101, Palo Alto CA 94304, USA. Fax: (650) 852-3111.Search for more papers by this authorK. K. Weinhardt, K. K. Weinhardt Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorM. Taylor, M. Taylor Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorA. DeSouza, A. DeSouza Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorP. M. McNeeley, P. M. McNeeley Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorK. Szczepanski, K. Szczepanski Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorD. J. Fontana, D. J. Fontana Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorJ. Trinh, J. Trinh Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorC. L. Rocha, C. L. Rocha Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorM. W. Dawson, M. W. Dawson Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorZ. Cao, Z. Cao Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorL. Wong, L. Wong Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this authorR. M. Eglen, R. M. Eglen Roche Bioscience, Palo Alto, CA 94304, USA.Search for more papers by this author First published: 29 September 2006 https://doi.org/10.1111/j.1527-3458.1997.tb00328.xCitations: 4AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Abrainowski D, Rigo M, Due D, Hoyer D, Staufenbiel M. Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 1995; 34: 163S– 1645. 2 Audia JE, Evard DA, Murdoch GR, et al. Potent, selective tetrahydro-β-carboline antagonists of the serotonin 2B (5-HT2B) contractile receptor in the rat stomach fundus. J Med Chem 1996; 39: 2773– 2780. 3 Baez M, Kursar JD, Helton LA, Wainscott DB, Nelson DL. Molecular biology of serotonin receptors. Obes Res Suppl 4 1995; 3: 441S– 447S. 4 Bagdy G, Kalogeras KT, Szemeredi K. Effect of 5-HT1C and 5-HT2 receptor stimulation on excessive grooming, penile erection, and plasma oxytocin concentrations. Eur J Pharmacol 1992; 229: 9– 14. 5 Baxter G, Kennett G, Blaney F, Blackburn T. 5-HT2 receptor subtypes: A family re-united Trends Pharmacol Sci 1995; 16: 105– 110. 6 Baxter GS, Murphy OE, Blackburn TP. Further characterization of 5-hydroxytryptamine receptors (the putative 5-HT2B) in rat stomach fundus longitudinal muscle. Br J Pharmacol 1994; 112: 323– 331. 7 Berendsen HH, Jenck F, Broekkamp CL. Involvement of 5-HT1C receptors in drug-induced penile erections in rats. Psychopharmacology 1990; 101: 57– 61. 8 Blavet N, DeFeudis FV, Clostre F. Inhibition of food intake in the rat by cyproheptadine. Experientia 1982; 38: 264– 265. 9 Bonhaus DW, Bach C, DeSouza A, et al. The pharmacology and distribution of human 5-hydroxytryp-tamine2B (5-HT2B) receptor gene products: Comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 1995; 115: 622– 628. 10 Bonhaus DW, Weinhardt KK, Taylor M, et al. RS-102221: A novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacoiogy 1997; 36: 621– 629. 11 Brewerton TD, Murphy DL, Mueller EA, Jimerson DC. Induction of migraine-like headaches by the serotonin agonist m-chlorophenylpiperazine. Clin Pharmacol Ther 1988; 43: 605– 609. 12 Bromidge SM, Duckworth M, Forbes IT, et al. 6-chloro-5-methyl-l-([2-(2-methyl-3-pyridyl)oxy]-5-pyri-dyl]carbamoyl)-indoline (SB-242084): The first selective and brain-penetrant 5-HT2C receptor antagonist. J Med Chem 1997; 740: 3494– 3496. 13 Callahan PM, Cunningham KA. Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (m-CPP). Eur J Pharmacol 1994; 257: 27– 38. 14 Chen Y, Baez M, Yu L. Functional coupling of the 5-HT2C serotonin receptor to G proteins in Xenopus oocytes. Neurosci Lett 1994; 179: 100– 102. 15 Choi DS, Maroteaux L. Immunohistochemical localisation of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain. FEBS Lett 1996; 391: 45– 51. 16 Conn PJ, Sanders-Bush E, Hoffman BJ, Hartig PR. A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. Proc Natl Acad Sci USA 1986; 83: 4086– 4088. 17 Curzon G, Kennen GA. m-CPP: A tool for studying behavioural responses associated with 5-HT1C receptors. Trends Pharmacol Sci 1990; 11: 181– 182. 18 Cutrer FM, Limmroth V, Ayata G, Moskowitz MA. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol 1995; 116: 3199– 3204. 19 Duxon MS, Flanigan TP, Reavley AC, Baxter GS, Blackburn TP, Fone KCF. Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system. Neuroscience 1997; 76: 323– 329. 20 Fiorella D, Helsley S, Rabin RA, Winter JC. 5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenyl piperazine. Psychopharmacology 1995; 122: 237– 243. 21 Fletcher PJ. Increased food intake in satiated rats induced by the 5-HT antagonists methysergide, meter-goline, and ritanserin. Psychopharmacology 1988; 96: 237– 242. 22 Foguet M, Nguyen H, Le H, Lubbert H. Structure of the mouse 5-HT1C, 5-HT2, and stomach fundus serotonin receptor genes. Neuroreport 1992; 3: 345– 348. 23 Forbes IT, Ham P, Booth DH, et al. 5-Methyl-l-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]in-dole: A novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity. J Med Chem 1995; 38: 2524– 2530. 24 Forbes IT, Kennett GA, Gadre A, et al. N-(1-methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: The first selective 5-HT1C receptor antagonist. J Med Chem 1993; 36: 1104– 1107. 25 Fozard JR. 5-HT1C receptor agon ism as an initiating event in migraine. In: J Olesen, PR Saxena, eds. 5-hydroxytryptamine mechanisms in primary headaches. New York : Raven Press, 1992;26: 200– 12. 26 Fozard JR, Gray JA. 5-HT1C receptor activation: A key step in the initiation of migraine Trends Pharmacol Sci 1989; 10: 307– 309. 27 Hoffman BJ, Mezey E. Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain. FEBS Lett 1989; 247: 453– 462. 28 Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharm Rev 1994; 46: 157– 203. 29 Hoyer D, Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res 1986; 376: 97– 107. 30 Hoyer D, Srivatsa S, Pazos A, Engel G, Palacios JM. [3H]LSD labels 5-HT1C recognition sites in pig choroid plexus membranes. Comparison with [3H]mesulergine and [3H]5-HT binding. Neurosci Lett 1986; 69: 269– 274. 31 Kahn RS, Wetzler S. m-Chorophenylpiperazine as probe of serotonin function. Biol Psychiatry 1991; 31: 1139– 1166. 32 Kalkman HO. Is migraine prophylactic activity caused by 5-HT2B or 5-HT2C receptor blockade Life Sci 1994; 54: 641– 644. 33 Kalkman HO, Hoyer D, Schoeffter P, et al. SDZ SER-08, a centrally acting 5-HT2C receptor antagonist. Proc. Third Satellite Meeting on Serotonin 1994; 70. 34 Kennett GA, Ainsworth K, Trail B, Blackburn TP. BW 723C86, a 5-HTCB receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacology 1997; 36: 233– 239. 35 Kennett GA, Bailey F, Piper DC, Blackburn TP. Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology 1995; 118: 178– 182. 36 Kennett GA, Bright F, Trail B, Baxter GS, Blackburn TP. Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety, Br J Pharmacol 1996; 117: 1443– 1448. 37 Kennett GA, Curzon G. Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors. Psychopharmacology 1988; 96: 93– 100. 38 Kennett GA, Curzon G. Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 1988; 94: 137– 147. 39 Kennett GA, Curzon G. Potencies of antagonists indicate that 5-HT1C receptors mediate 1-3(chlorophe-nyl)piperazine-induced hypophagia. Br J Pharmacol 1991; 103: 2016– 2020. 40 Kennet GA, Pittaway K, Blackburn TP. Evidence that 5-HT2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology 1994; 114: 90– 96. 41 Kennett GA, Wood MD, Bright F, et al. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 1996; 117: 427– 434. 42 Kennett GA, Wood MD, Bright F, et al. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Newopharmacology 1997; 36: 609– 620. 43 Kennett GA, Wood MD, Glen A, et al. In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol 1994; 111: 797– 802. 44 Kenne JH, Baron BM, Carr AA, et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 1996; 277: 968– 981. 45 Klodzinska A, Jaros T, Chojnacka-Wojcik E, Maj J. Exploratory hypoactivity induced by m-trifluoro-methylphenylpiperazine (TFMPP) and m-chlorophenylpiperazine (m-CPP). J Neural Transmission 1989; 1: 207– 218. 46 Kursar JD, Nelson DL, Wainscott DB, Cohen ML, Baez M. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine-2F) from rat stomach fundus. Mol Pharmacol 1992; 42: 549– 557. 47 Martin GR, Humphrey PPA. Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Newopharmacology 1994; 33: 261– 273. 48 Mazzola-Pomietto P, Aulakh CS, Wozniak KM, Hill JL, Murphy DL. Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors. Psychopharmacology 1995; 117: 193– 199. 49 Mazzola-Pomietto P, Aulakh CS, Wozniak KM, Murphy DL. Evidence that m-chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT2C receptors. Psychopharmacology 1996; 123: 333– 339. 50 McConnell HM, Owicki JC, Parce JW, et al. The cytosensor microphysiometer: Biological applications of silicon technology. Science 1992; 257: 1906– 1912. 51 Millan MJ, Peglion JL, Lavielle G, Perrin-Monneyron S. 5-HT2C receptors mediate penile erections in rats: Actions of novel and selective agonists and antagonists. Eur J Pharmacol 1997; 325: 9– 12. 52 Molineaux SM, Jessell TM, Axel R, Julius D. 5-HT1C receptor is a prominent serotonin receptor subtype in the central nervous system. Proc Natl Acad Sci USA 1989; 86: 6793– 6797. 53 Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993; 43: 816– 20. 54 Mylecharane EJ. 5-HT2 receptor antagonists and migraine therapy. J Neurol Suppl 1 1991; 238: S45– S52. 55 Nozulak J, Kalkman HO, Floersheim P, Hoyer D, Schoeffter P, Buerki HR. (+)-cis-4,5,7a,8,9,10,11,11la-octahy-dro-7H-10-methylindolo(1,7-bcX2,6)-naphthyridine: A 5-HT2C/2B receptor antagonist with low 5-HT1A receptor affinity. J Med Chem 1995; 38: 28– 33. 56 Pazos A and Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in rat brain. I. Serotonin receptors. Brain Res 1985; 345: 205– 230. 57 Pazos A, Hoyer D, Palacios JM. The binding of serotonergic ligands to the porcine choroid plexus: Characterization of a new type of serotonin recognition site. Eur J Pharmacol 1984; 106: 539– 546. 58 Saltzman AG, Morse B, Whitman MM, Ivanshchenko Y, Jaye M, Felder S. Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes. Biochem Biophys Res Commun 1991; 181: 1469– 1478. 59 Schmuck K, Ullmer C, Kalkman HO, Probst A, Lübbert H. Activation of meningeal 5-HT2B receptors: An early step in the generation of migraine headache Eur J Neurosci 1996; 8: 959– 967. 60 Shih JC, Yang W, Chen K, Gallaher T. Molecular biology of serotonin (5-HT) receptors. Pharmacol Biochem Behav 1991; 40: 1053– 1058. 61 Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995; 374: 542– 546. 62 Trail B, Ainsworth K, Blackburn TP, et al. Are mCPP-induced behaviours 5-HT2C or 5-HT2 receptor-mediated Br J Pharmacol 1995; 116: 449P. 63 Weinhardt KK, Bonhaus DW, DeSouza A. Some benzenesulfonamido-substituted valerophenones that are selective antagonists for the 5-HT1C receptor. Bioorgan Med Chem Lett 1996; 6: 2687– 2692. Citing Literature Volume3, Issue3September 1997Pages 278-293 ReferencesRelatedInformation" @default.
• W1993422879 created "2016-06-24" @default.
• W1993422879 creator A5003167289 @default.
• W1993422879 creator A5021593027 @default.
• W1993422879 creator A5024671849 @default.
• W1993422879 creator A5030674185 @default.
• W1993422879 creator A5057058034 @default.
• W1993422879 creator A5060384953 @default.
• W1993422879 creator A5070529034 @default.
• W1993422879 creator A5070800169 @default.
• W1993422879 creator A5071451676 @default.
• W1993422879 creator A5072070682 @default.
• W1993422879 creator A5072148312 @default.
• W1993422879 creator A5082366357 @default.
• W1993422879 creator A5088105419 @default.
• W1993422879 date "1997-09-01" @default.
• W1993422879 modified "2023-10-15" @default.
• W1993422879 title "Biochemical and Behavioral Pharmacology of RS-102221, a Subtype Selective 5-HT_2cReceptor Antagonist" @default.
• W1993422879 cites W1970015753 @default.
• W1993422879 cites W1972047614 @default.
• W1993422879 cites W1977591229 @default.
• W1993422879 cites W1981710409 @default.
• W1993422879 cites W1982931433 @default.
• W1993422879 cites W1984692581 @default.
• W1993422879 cites W1987187456 @default.
• W1993422879 cites W1989352400 @default.
• W1993422879 cites W1990635904 @default.
• W1993422879 cites W1992202855 @default.
• W1993422879 cites W1993000687 @default.
• W1993422879 cites W1996140740 @default.
• W1993422879 cites W1998573871 @default.
• W1993422879 cites W2001327571 @default.
• W1993422879 cites W2010364329 @default.
• W1993422879 cites W2010595984 @default.
• W1993422879 cites W2013056388 @default.
• W1993422879 cites W2013386552 @default.
• W1993422879 cites W2021383362 @default.
• W1993422879 cites W2022784192 @default.
• W1993422879 cites W2022931431 @default.
• W1993422879 cites W2024952531 @default.
• W1993422879 cites W2025678690 @default.
• W1993422879 cites W2035632600 @default.
• W1993422879 cites W2036054091 @default.
• W1993422879 cites W2036213823 @default.
• W1993422879 cites W2038500073 @default.
• W1993422879 cites W2038620688 @default.
• W1993422879 cites W2038946536 @default.
• W1993422879 cites W2041457090 @default.
• W1993422879 cites W2044799822 @default.
• W1993422879 cites W2054194857 @default.
• W1993422879 cites W2054287670 @default.
• W1993422879 cites W2054437319 @default.
• W1993422879 cites W2056761692 @default.
• W1993422879 cites W2058313885 @default.
• W1993422879 cites W2058556149 @default.
• W1993422879 cites W2059279128 @default.
• W1993422879 cites W2063085120 @default.
• W1993422879 cites W2064455131 @default.
• W1993422879 cites W2074392685 @default.
• W1993422879 cites W2081780864 @default.
• W1993422879 cites W2082355365 @default.
• W1993422879 cites W2085082789 @default.
• W1993422879 cites W2085829376 @default.
• W1993422879 cites W2089210700 @default.
• W1993422879 cites W2090369849 @default.
• W1993422879 cites W2095106761 @default.
• W1993422879 cites W2095131733 @default.
• W1993422879 cites W2120784459 @default.
• W1993422879 cites W2138765408 @default.
• W1993422879 cites W2164938770 @default.
• W1993422879 cites W2328809607 @default.
• W1993422879 cites W2331337476 @default.
• W1993422879 cites W2923096336 @default.
• W1993422879 doi "https://doi.org/10.1111/j.1527-3458.1997.tb00328.x" @default.
• W1993422879 hasPublicationYear "1997" @default.
• W1993422879 type Work @default.
• W1993422879 sameAs 1993422879 @default.
• W1993422879 citedByCount "1" @default.
• W1993422879 crossrefType "journal-article" @default.
• W1993422879 hasAuthorship W1993422879A5003167289 @default.
• W1993422879 hasAuthorship W1993422879A5021593027 @default.
• W1993422879 hasAuthorship W1993422879A5024671849 @default.
• W1993422879 hasAuthorship W1993422879A5030674185 @default.
• W1993422879 hasAuthorship W1993422879A5057058034 @default.
• W1993422879 hasAuthorship W1993422879A5060384953 @default.
• W1993422879 hasAuthorship W1993422879A5070529034 @default.
• W1993422879 hasAuthorship W1993422879A5070800169 @default.
• W1993422879 hasAuthorship W1993422879A5071451676 @default.
• W1993422879 hasAuthorship W1993422879A5072070682 @default.
• W1993422879 hasAuthorship W1993422879A5072148312 @default.
• W1993422879 hasAuthorship W1993422879A5082366357 @default.
• W1993422879 hasAuthorship W1993422879A5088105419 @default.
• W1993422879 hasBestOaLocation W19934228791 @default.
• W1993422879 hasConcept C126322002 @default.
• W1993422879 hasConcept C15744967 @default.
• W1993422879 hasConcept C169760540 @default.
• W1993422879 hasConcept C170493617 @default.
• W1993422879 hasConcept C185592680 @default.

• next